Items where authors include "Ritchlin, CT"

Article

McGonagle, D, McInnes, IB, Deodhar, A et al. (10 more authors) (2023) Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology, 5 (4). pp. 227-240. ISSN 2578-5745

Orbai, A-M, Coates, LC, Deodhar, A et al. (10 more authors) (2022) Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. The Patient: Patient Centered Outcomes Research, 15 (6). pp. 657-668. ISSN 1178-1653

Ritchlin, CT, Giles, JT, Ogdie, A et al. (8 more authors) (2020) Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatology, 2 (10). pp. 543-554. ISSN 2578-5745

Goel, N, Coates, LC orcid.org/0000-0002-4756-663X, De Marco, G orcid.org/0000-0003-2406-161X et al. (11 more authors) (2020) GRAPPA 2019 Project Report. The Journal of Rheumatology Supplement, 96. pp. 53-57. ISSN 0380-0903

Deodhar, A, Helliwell, PS, Boehncke, W-H et al. (9 more authors) (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 395 (10230). pp. 1115-1125. ISSN 0140-6736

Mease, PJ, Gladman, DD, Collier, DH et al. (5 more authors) (2019) Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis & Rheumatology, 71 (7). pp. 1112-1124. ISSN 2326-5191

Goel, N, FitzGerald, O, Gladman, DD et al. (6 more authors) (2019) GRAPPA 2018 Project Report. The Journal of Rheumatology Supplement, 95. pp. 54-57. ISSN 0380-0903

Jadon, DR, Chandran, V, Ogdie, A et al. (12 more authors) (2019) Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. The Journal of Rheumatology Supplement, 95. pp. 11-19. ISSN 0380-0903

Jadon, DR, Chandran, V, Stober, C et al. (9 more authors) (2018) Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting. The Journal of Rheumatology, 94 (S). pp. 54-61. ISSN 0380-0903

Veale, DJ, McGonagle, D, McInnes, IB et al. (8 more authors) (2018) The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology. key070. ISSN 1462-0324

Coates, LC orcid.org/0000-0002-4756-663X, Gossec, L, Smolen, JS et al. (5 more authors) (2017) New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. Rheumatology, 56 (8). pp. 1251-1253. ISSN 1462-0324

Jadon, DR, Gladman, DD, Mease, PJ et al. (19 more authors) (2017) Proceedings of the GRAPPA 2016 Retreat. The Journal of Rheumatology, 44 (5). pp. 668-673. ISSN 0315-162X

Kavanaugh, A, Helliwell, P and Ritchlin, CT (2016) Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatology and Therapy, 3 (1). pp. 91-102. ISSN 2198-6576

Conference or Workshop Item

Ritchlin, CT, Rahman, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2021) Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials. In: AAD VMX 2021, 23-25 Apr 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 Discover-1 Trial. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Ritchlin, CT, Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (13 more authors) (2021) Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through 1 Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (8 more authors) (2020) AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. In: EULAR 2020, 03-06 Jun 2020, Online.

Ritchlin, CT, Ogdie, A, Giles, JT et al. (9 more authors) (2020) AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS. In: EULAR 2020, 03-06 Jun 2020, Online.

Rahman, P, Ritchlin, CT, Helliwell, P et al. (13 more authors) (2020) FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. In: EULAR 2020, 03-06 Jun 2020, Online.

Ritchlin, CT, Helliwell, P, Boehncke, WH et al. (8 more authors) (2020) SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. In: EULAR 2020, 03-06 Jun 2020, Online.

Proceedings Paper

Helliwell, P, Deodhar, A, Gottlieb, AB et al. (7 more authors) (2019) Comparing Composite Measures of Disease Activity in Psoriatic Arthritis: Results From a Randomized Phase 2 Trial with Guselkumab. In: Annals of the Rheumatic Diseases. EULAR 2019: Annual European Congress of Rheumatology, 12-15 Jun 2019, Madrid, Spain. BMJ Publishing Group , p. 1843.